Company Update (NYSE MKT:ISR): IsoRay, Inc.’s Cesium-131 Cancer Fighting Portfolio Was on Display at the American Association Of Physicists in Medicine (Aapm) Convention
IsoRay, Inc. (NYSEMKT:ISR) , a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced it participated at the American Association of Physicists in Medicine by hosting a private dinner and booth display. The annual AAPM meeting took place July 12-16, 2015 at the Anaheim Convention Center in Anaheim, California.
IsoRay CEO Dwight Babcock commented, “IsoRay is pleased to once again participate at the AAPM annual meeting. At this venue, we have a great opportunity to meet physicists from major institutions who are instrumental in the dosimetry planning for the use of Cesium-131 for a specific patient’s treatment. With peer reviewed publications continuing to show the positive results patients are achieving with the use of Cesium-131, physicists are increasingly becoming interested in the innovative alternative our Cesium-131 products offer the patient.”
IsoRay’s various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite® radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay’s cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life. Cesium-131 is now being used for the treatment of a wide array of cancers throughout the body including brain, lung, head and neck, chest wall, prostate and gynecologic cancers. (Original Source)
Shares of IsoRay opened today at $1.42 and are currently trading down at $1.41. ISR has a 1-year high of $3.79 and a 1-year low of $1.22. The stock’s 50-day moving average is $1.54 and its 200-day moving average is $1.54.
On the ratings front, Maxim Group analyst Jason Kolbert reiterated a Buy rating on ISR, with a price target of $5, in a report issued on May 21. The current price target implies an upside of 254.6% from current levels. According to TipRanks.com, Kolbert has a total average return of 0.6%, a 41.3% success rate, and is ranked #1944 out of 3707 analysts.
IsoRay Inc offers solutions for the treatment and diagnosis of disease using medical isotopes.